Indications |
Oral Obesity Adult: 120 mg tid with each main meal containing fat; omit dose if meal is occasionally missed or has no fat. Child: ≥12 yr: 120 mg tid with each main meal containing fat; omit dose if meal is occasionally missed or has no fat. |
Contraindications |
Chronic malabsorption syndrome. Cholestasis. Lactation. |
Warnings / Precautions |
Distribute daily intake of fat over 3 main meals. Fat-soluble vitamins supplements may be required during long-term therapy. Discontinue use if 5% body wt loss is not achieved during the first 12 wk. History of hyperoxaluria or calcium oxalate nephrolithiasis. DM. Pregnancy. |
Adverse Reactions |
Faecal urgency and incontinence, flatulence, fatty stools or discharge, increased defecation; headache, anxiety, fatigue, menstrual irregularities; abdominal pain/discomfort. Potentially Fatal: Anaphylaxis; angioedema. |
Drug Interactions |
May decrease absorption of oral fat-soluble vitamins, amiodarone, propafenone. May decrease plasma levels of ciclosporin. May alter the effects of warfarin (monitor INR). May elevate plasma levels of pravastatin. See Below for More orlistat Drug Interactions |
Mechanism of Actions |
Orlistat is a reversible gastric and pancreatic lipase inhibitor. It exerts antiobesity effects by limiting the absorption of dietary fats through inhibition of triglyceride hydrolysis. It does not exert appetite suppressant effects. Onset: 24-48 hr. Duration: 48-72 hr. Absorption: Minimally absorbed (oral). Metabolism: Metabolised to inactive metabolites within the GI wall. Excretion: Mainly via faeces (83% as unchanged drug). |
Administration |
Should be taken with food. (Take immediately before or during or up to 1 hr after each main meal. If a meal is missed or contains no fat, the dose may be omitted.) |
Storage Conditions |
Oral: Store at 15-30°C (59-86°F). |
ATC Classification |
A08AB01 - orlistat ; Belongs to the class of peripherally acting antiobesity products. |
Storage |
Oral: Store at 15-30°C (59-86°F). |
Available As |
|
Orlistat
Post Review about Orlistat Click here to cancel reply.
Orlistat Containing Brands
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.